VISINE L.R. Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Visine L.r., and when can generic versions of Visine L.r. launch?
Visine L.r. is a drug marketed by Johnson And Johnson and is included in one NDA.
The generic ingredient in VISINE L.R. is oxymetazoline hydrochloride. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the oxymetazoline hydrochloride profile page.
Summary for VISINE L.R.
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 67 |
Clinical Trials: | 1 |
Patent Applications: | 2,096 |
Formulation / Manufacturing: | see details |
DailyMed Link: | VISINE L.R. at DailyMed |
Recent Clinical Trials for VISINE L.R.
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Massachusetts Eye and Ear Infirmary | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for VISINE L.R.
US Patents and Regulatory Information for VISINE L.R.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Johnson And Johnson | VISINE L.R. | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019407-001 | Mar 31, 1989 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |